Bionyra Pharma’s pipeline includes two drugs that target the signaling protein TL1A, alone and as part of a combination approach to treat inflammatory disorders. The startup’s launch makes it a contender in an emerging drug class that includes late-clinical assets from Merck, Roche, and partners Sanofi and Teva Pharmaceuticals.
The post Inflammation Startup Bionyra Launches With $165M and Ex-Sanofi Exec at the Helm appeared first on MedCity News.
